Three Questions Pfizer Inc. Must Answer Regarding Its $99 Billion AstraZeneca PLC Bid

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

This morning, Pfizer confirmed that it had asked AstraZeneca to consider a merger, and been rebuffed. Under U.K. law, it had to disclose the offer and went public with a $98.7 billion offer to buy the London-based drug maker. The deal will be 70% cash and 30% stock, and will provide Pfizer with a way to use funds it has kept out of the U.S. without paying U.S. taxes. The deal would also allow Pfizer to lower its tax rate by creating a holding company in the U.K.

Hey, check out all the research scientist jobs. Post your resume today!

Back to news